Validation of the Global Allergy and Asthma European Network (GA2LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber

[1]  W. Fokkens,et al.  Measurements of nasal airflow and patency: a critical review with emphasis on the use of peak nasal inspiratory flow in daily practice , 2016, Allergy.

[2]  S. Vieths,et al.  Environmental exposure chambers in allergen immunotherapy trials: Current status and clinical validation needs. , 2015, The Journal of allergy and clinical immunology.

[3]  R. Jacobs,et al.  Effect of confounding cofactors on responses to pollens during natural season versus pollen challenge chamber exposure. , 2014, The Journal of allergy and clinical immunology.

[4]  J. Bousquet,et al.  Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. , 2014, Allergy.

[5]  O. Pfaar,et al.  The placebo effect in allergen-specific immunotherapy trials , 2013, Clinical and Translational Allergy.

[6]  P. Bousquet,et al.  Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  P. Zieglmayer.  Are results of environmental exposure units transferable to real-life exposure? , 2013, Current opinion in allergy and clinical immunology.

[8]  J. Bernstein.  Correlation between a pollen challenge chamber and a natural allergen exposure study design for eliciting ocular and nasal symptoms: early evidence supporting a paradigm shift in drug investigation? , 2012, The Journal of allergy and clinical immunology.

[9]  R. Jacobs,et al.  Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes. , 2012, The Journal of allergy and clinical immunology.

[10]  P. Howarth,et al.  Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients , 2012, Allergy.

[11]  P. Howarth,et al.  How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA‐GA2LEN statement , 2011, Allergy.

[12]  N. Krug,et al.  Anti-allergic drug testing in an environmental challenge chamber is suitable both in and out of the relevant pollen season. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[13]  P. Devillier,et al.  The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy , 2011, Allergy.

[14]  P. Patel,et al.  Mometasone Furoate Nasal Spray Provides Early, Continuing Relief of Nasal Congestion and Improves Nasal Patency in Allergic Patients , 2010, American journal of rhinology & allergy.

[15]  T. Holland-Letz,et al.  Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  F. Horak,et al.  The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber , 2010, Inflammation Research.

[17]  P. Devillier,et al.  Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. , 2009, The Journal of allergy and clinical immunology.

[18]  H. Malling,et al.  Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. , 2008, The Journal of allergy and clinical immunology.

[19]  S. Kunjibettu,et al.  Onset of Action of Ciclesonide Once Daily in the Treatment of Seasonal Allergic Rhinitis , 2008, Ear, nose, & throat journal.

[20]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[21]  J. Bousquet,et al.  Original article: Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines , 2007, Allergy.

[22]  G. Canonica,et al.  The role of allergen challenge chambers in the evaluation of anti‐allergic medication: an international consensus paper , 2006 .

[23]  C. Salome,et al.  Repeatability of peak nasal inspiratory flow measurements and utility for assessing the severity of rhinitis , 2005, Allergy.

[24]  N. Krug,et al.  Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[25]  S. Spector,et al.  Symptom severity assessment of allergic rhinitis: part 1. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[26]  F. Horak,et al.  Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. , 1998, Journal of investigational allergology & clinical immunology.

[27]  J. H. Day,et al.  Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[28]  J. Mullol,et al.  Placebo effect in clinical trials involving patients with allergic rhinitis. , 2011, Journal of investigational allergology & clinical immunology.

[29]  R. Kawata,et al.  Evaluating the effects of testing period on pollinosis symptoms using an allergen challenge chamber. , 2011, Allergology international : official journal of the Japanese Society of Allergology.

[30]  S. Kunjibettu,et al.  Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.